The German-Austrian AML Study Group conducted a study to evaluate genetic mutations and clinical outcomes in 872 adults younger than 60 years of age and again demonstrated that NPM1 mutation without FLT3ITD was associated with lower risk of relapse and death [34]. This evidence concerns the gene NPM1 and acute myeloid leukemia.